Zhizhuang Zhao to Mice, Transgenic
This is a "connection" page, showing publications Zhizhuang Zhao has written about Mice, Transgenic.
Connection Strength
0.687
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
Score: 0.158
-
Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. PLoS One. 2014; 9(7):e99017.
Score: 0.105
-
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol. 2014 Jul 15; 193(2):477-84.
Score: 0.105
-
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol. 2014 Mar 19; 7:25.
Score: 0.103
-
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008 May 15; 111(10):5109-17.
Score: 0.068
-
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 04 06; 2(7):e90932.
Score: 0.032
-
Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry. PLoS One. 2014; 9(4):e93643.
Score: 0.026
-
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6091-6.
Score: 0.024
-
Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation. Bioorg Med Chem Lett. 2012 Feb 01; 22(3):1402-7.
Score: 0.022
-
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11):1058-68.
Score: 0.022
-
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth. Exp Hematol. 2012 Jan; 40(1):22-34.
Score: 0.022